PT - JOURNAL ARTICLE AU - Luc Cabel AU - Elika Loir AU - Gwenaelle Gravis AU - Pernelle Lavaud AU - Christophe Massard AU - Laurence Albiges AU - Giulia Baciarello AU - Yohann Loriot AU - Karim Fizazi TI - Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients AID - 10.1186/s40425-017-0232-7 DP - 2017 Dec 01 TA - Journal for ImmunoTherapy of Cancer PG - 31 VI - 5 IP - 1 4099 - http://jitc.bmj.com/content/5/1/31.short 4100 - http://jitc.bmj.com/content/5/1/31.full SO - J Immunother Cancer2017 Dec 01; 5 AB - Background Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic castrate-resistant prostate cancer (mCRPC), thanks to next-generation androgen receptor axis targeted drugs, taxanes, and bone-targeted agents, immunotherapy has not been widely approved and used for the treatment of prostate cancer. Two large studies with ipilimumab, an anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) antibody reported improved progression-free survival, but not statistically improved overall survival at the primary analysis (CA184 043 and CA184 095).Case presentation Here, we report on two patients who received ipilimumab in these trials and are still in long-term complete remission with a follow-up of 64 and 52 months respectively after the initiation of ipilimumab. Immunohistochemical staining for hMLH1, hMSH2, hMSH6 and PMS2 was performed on archival prostate biopsy samples from one of the two patients; they exhibited normal protein expression. Interestingly for this patient, a high CD3+ and CD8+ T cell infiltration was observed on archival prostate biopsies as well as Treg FoxP3+ T cells.Conclusion Ipilimumab produces clinical activity in patients with CRPC, including very long responders with no detectable residual disease.Abbreviations:HRHazard ratiomCRPCMetastatic castrate-resistant prostate cancerOSOverall survivalPFSProgression-free survivalPSAProstate-specific-antigenTILTumor-infiltrating lymphocytes